지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 1,164 - 1,174 (11page)
이용수
초록· 키워드
오류제보하기
Purpose Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. However, little is known about how it works among patients with various timings of T790M emergence and treatment. Materials and Methods Advanced EGFR-mutant lung adenocarcinoma patients with positive T790M mutation in tumor were retrospectively enrolled and observed to determine the outcomes of osimertinib treatment. We evaluated the association between patients’ characteristics and the efficacy of osimertinib treatment, particularly with respect to the timing of T790M emergence and osimertinib prescription. Results A total of 91 patients were enrolled, including 14 (15.4%) with primary and 77 (84.6%) with acquired T790M mutation. The objective response rate and disease control rate were 60.9% and 85.1%, respectively. The median progression-free survival (PFS) and overall survival were 11.5 months (95% confidence interval [CI], 9.0 to 14.0) and 30.4 months (95% CI, 11.3 to 49.5), respectively. There was no significant difference in response rate and PFS between primary and acquired T790M populations. In the acquired T790M subgroup, patients who received osimertinib after T790M had been confirmed by rebiopsy had a longer PFS than those with intercalated treatments between rebiopsy and osimertinib prescription (14.0 months [95% CI, 9.0 to 18.9] vs. 7.2 months [95% CI, 3.7 to 10.8]; adjusted hazard ratio, 0.48 [95% CI, 0.24 to 0.98; p=0.043]). Rebiopsy timing did not influence the outcome. Conclusion Osimertinib prescription with intercalated treatment following rebiopsy but not the timing of T790M emergence influenced the treatment outcome. We suggest that it is better to start osimertinib treatment once T790M mutation has been confirmed by biopsy.
목차
등록된 정보가 없습니다.
참고문헌 (30)
참고문헌 신청
Cancer Genome Atlas Research Network / 2014 / Comprehensive molecular profiling of lung adenocarcinoma / Nature 511:543~550
Hsu KH / 2015 / Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan / PLoS One 10:e0120852
Greenhalgh J / 2016 / First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous nonsmall cell lung cancer / Cochrane Database Syst Rev (5)
Thongprasert S / 2011 / Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) / J Thorac Oncol 6:1872~1880
Jackman D / 2010 / Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer / J Clin Oncol 28:357~360
Hsu KH / 2015 / Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan / PLoS One 10:e0120852
Greenhalgh J / 2016 / First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous nonsmall cell lung cancer / Cochrane Database Syst Rev (5)
Thongprasert S / 2011 / Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) / J Thorac Oncol 6:1872~1880
Jackman D / 2010 / Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer / J Clin Oncol 28:357~360
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Cancer Research and Treatment
2022 .10
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .01
-
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
2018 .01
-
Outcome After Protontherapy for Progression or Recurrence of Surgically Treated Meningioma
Brain Tumor Research and Treatment
2021 .10
-
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Cancer Research and Treatment
2020 .01
-
Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
Cancer Research and Treatment
2019 .01
-
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Cancer Research and Treatment
2022 .04
-
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
Cancer Research and Treatment
2020 .01
-
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Cancer Research and Treatment
2020 .01
-
지역사회 거주 노인의 낙상 경험 영향요인: 2021년 지역사회건강조사 활용
한국직업건강간호학회지
2023 .05
-
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Cancer Research and Treatment
2016 .01
-
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
Yonsei Medical Journal
2019 .01
-
Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis
Journal of Gynecologic Oncology
2022 .09
-
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
Investigative and Clinical Urology
2020 .01
-
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment
2017 .01
-
병원 밖 심정지 환자의 응급실 생존 퇴원 영향요인
보건교육건강증진학회지
2025 .03
-
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment
Cancer Research and Treatment
2021 .10
-
Contrast-Induced Acute Kidney Injury after Coil Embolization for Aneurysmal Subarachnoid Hemorrhage
Yonsei Medical Journal
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0